The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial.

Plain-language guide to PMID 29728074 (2018): open-label randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 29728074
Journal: BMC public health
Year: 2018
Study type: Randomized Controlled Trial
Authors: Bullen C et al. (8 authors)
DOI: 10.1186/s12889-018-5351-7

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Quit attempts using "gold standard" smoking cessation treatments often fail in people with these conditions, so more flexible treatment regimens that adapt to a person's responsiveness to treatment are worth investigating.

Australian NZ Clinical Trial Registry: ACTRN12616001355460 (29 September 2016).

Who Took Part

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Nothing was hidden in this open-label Therapeutic nicotine (patch, non-peptide) study: the participants and staff both knew the treatment.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

This is a pragmatic two-arm, open-label, randomised trial.

The primary outcome is self-reported biochemically-verified (exhaled carbon monoxide) continuous abstinence at 24 weeks post-randomisation.

What Was Measured

The subject headings attached to it are Combined Modality Therapy, Electronic Nicotine Delivery Systems, Mental Disorders, Motivation, Smoking, Smoking Cessation and Substance-Related Disorders.

Author keywords: Addiction, E-cigarettes, Effectiveness, Electronic cigarettes, Mental illness and Randomised trial.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (BMC public health), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.